News Update

Cell Therapy Company and Chinese Firm Sign Marketing Deal

  ()
This biotech, in Phase 1 development of regenerative technologies addressing skin and orthopedic indications, has finalized a commercialization deal with YOFOTO. read more >
News Update

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

  ()
A poster outlining data from this company's lead candidate, which targets toxic oligomers identified as a potential cause of Alzheimer's disease, will be presented at the Alzheimer's Association International Conference (AAIC). read more >

Coverage Initiated on 'True Original' Using RNAi to Enhance Cancer Immunotherapy

Research Report
  ()
An H.C. Wainwright & Co. report outlined the thesis for investing in this emerging biotech. read more >

Study Shows Biopharma's Lead Drug Mediates T Cell Tumor Infiltration

Research Report
  ()
An Echelon Wealth Partners report discussed this firm's stock performance and how a recent clinical trial update impacted it. read more >

Three Companies Poised to Benefit from Proposed Medicare Home Health Monitoring Change

  ()
A proposed rule change would allow Medicare to reimburse home health agencies for remote patient monitoring, providing an opportunity for health technology companies. read more >

EpiPen Rival Lands Major Partner

Research Report
  ()
An H.C. Wainwright & Co. report explains the deal, which concerns a new single-dose epinephrine injection for severe allergic reactions. read more >

Target Price Increased on Biotech After Q2/18 Revenue Record, Beat

Research Report
  ()
A Maxim Group report explained the likely reasons behind revenue growth for the firm, which produces media used in development of cell therapies. read more >

Immunotherapy Firm's Triple Combination Trial for Glioblastoma Sees First Patient Dosed

Research Report
  ()
A Maxim Group note discussed the latest clinical endeavor involving a three-pronged approach targeting glioblastoma. read more >

Coverage Initiated on Biopharma with 'Opioid Sparing Solution for Post-Op Pain'

Research Report
  ()
An H.C. Wainwright & Co. report highlighted the advantages, status and potential of this lead asset. read more >
Breaking News

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase

  ()
This precision medicine company, focused on neurodegenerative diseases, has selected antibody candidates to advance into the final phase of discovery. read more >
Expert Investing Ideas

"We are initiating coverage on PMN."

–John Vandermosten, Zacks Small-Cap Research


"DRRX reported its Q1/18, mostly in line with expectations."

–Francois Brisebois, Laidlaw & Company


"PMN is seeking to forge partnerships with big pharmas."

–André Uddin, Mackie Research Capital


"We believe 2018 could prove to be a pivotal year for DRRX."

–Francois Brisebois, Laidlaw & Company


"We continue to be positive about DRRX's story."

–Grant Zeng, Zacks Small-Cap Research


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Coverage Initiated on Immunotherapy Developer with Phase 3 Lead Asset

Research Report
  ()
A B. Riley FBR report provided an overview of this life sciences firm. read more >

Transfusion Medicine Biotech Hits Target on Road to Commercialization

Research Report
  ()
A BTIG report reviewed the news announced by this supplier of blood grouping reagents and control products. read more >

Agreement Facilitates Progress Toward Medical Device Approvals

  ()
This medical device company enters a partnership to provide quality and regulatory services. read more >
News Update

Biotech Targeting Alzheimer's Disease Advances Toward Phase 1

  ()
Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease. read more >